definiens: within the meaning of thePrivate Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning : thecontinued expansion of [COMPANY] ’ portfolio of medicines in psychiatry, the continued clinical development and thepotential therapeutic and commercial value of ALKS 8700 for the treatment of relapsing forms of MS, the number ofpatients enrolled in the ALKS 8700 Phase 3 studies, the timing of expected initial data from EVOLVE - MS-2, theregulatory strategy for filing of an NDA for ALKS 8700 and the adequacy of the EVOLVE - MS development program forALKS 8700 to serve as the basis for an NDA, the timing of the submission of an NDA to the FDA for ALKS 8700 and thepotential financial, commercial and therapeutic benefits that may be achieved through collaboration with [COMPANY] underthe license and collaboration agreement between [COMPANY] and [COMPANY] . [COMPANY] cautions that forward - lookingstatements are inherently uncertain . Although [COMPANY] believes that such statements are based on reasonableassumptions within the bounds of its knowledge of its business and operations, the forward - looking statements areneither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk . Actualperformance and results may differ materially from those expressed or implied in the forward - looking statements due tovarious risks and uncertainties . These risks and uncertainties include, among others : whether the results from the head - to - head study to evaluate the GI tolerability of ALKS 8700 compared to TECFIDERA will show that ALKS 8700 hasmore favorable GI tolerability ; whether preclinical and early clinical results for ALKS 8700 will be predictive of futureclinical study results or real - world results ; whether clinical trials for ALKS 8700 will be completed on time or at all;changes in the cost, scope and duration of the ALKS 8700 clinical trials ; whetherF – Press Release ALKS 8700 could be shown ineffective or unsafe during clinical studies, and whether, in such instances, [COMPANY] maynot be permitted by regulatory authorities to undertake new or additional clinical studies of ALKS 8700 ; whetherregulatory submissions for ALKS 8700 will be submitted on time or at all ; whether adverse decisions by regulatoryauthorities will occur ; whether the pharmacokinetic, Phase 3 and other studies conducted for ALKS 8700 will meet theFDA ’s requirements for approval ; whether the potential financial, commercial and therapeutic benefits of collaborationwith [COMPANY] under the license and collaboration agreement between [COMPANY] and [COMPANY] will be achieved ; and thoserisks described in the [COMPANY] Annual Report on Form 10 - K for the fiscal year ended December 31, 2016, andQuarterly Reports on Form 10 - Q for the quarters ended March 31, 2017 and September 30, 2017 and in subsequentfilings made by [COMPANY] with the U.S. Securities and Exchange Commission ( SEC ), which are available on the SEC’swebsite at www.sec.gov . Existing and prospective investors are cautioned not to place undue reliance on these forward - looking statements, which speak only as of the date hereof . Except as required by law, the company disclaims anyintention or responsibility for updating or revising any forward - looking statements contained in this press release